Shanghai AI Industry Investment Fund
上海人工智能产业投资基金
The Shanghai AI Industry Investment Fund is a government-backed sector fund that invests across artificial intelligence and related hard-tech domains. Per a 2021 5Y Capital piece, it led the strategic funding round for AI drug-discovery firm Galixir (星药科技) in August of that year, with Gaorong Capital, Source Code Capital, Redpoint China, DCM, 5Y Capital and BAI Capital among the co-investors . More recently, it has backed companies including large-model developer Baichuan , humanoid-robot maker Galaxy Universal (银河通用) , and AI infrastructure startup Infinigence AI (无问芯穹) , as reported by SoulCapital, Source Code Capital, BlueRun Ventures and Oasis Capital between 2024 and late 2024. It also joined the Series A4 round of data-intelligence firm Deepexi in 2020 . The fund sits within a broader Shanghai policy push: in mid-2024 the city launched a 22.5 billion RMB AI-focused mother fund—described as the largest of its kind in China—with 11 intended LP partners, alongside parallel vehicles for integrated circuits and biopharma .
AI-generated — may contain errors, please verify.
Coverage
MaKe | MaHui Member Galaxy Universal Completes 500 Million RMB Strategic Funding Round
Galaxy Universal Raises 500 Million Yuan in Strategic Funding Round | BlueRun Ventures Headlines
Embodied Intelligence Powers a New Future for General-Purpose Robotics
Infinigence AI Raises Nearly RMB 1 Billion in Total Funding, Aiming to Become the Go-To "Compute Operator" in the LLM Era | Oasis Vitality
Advisor on Vitality
Heart Capital Leads Series A Investment in Baichuan, Continues AI Sector Bet | HeartStar PORTFOLIO
The funding round reached 5 billion yuan.
4 Companies Raise Nearly 2 Billion RMB in Total | FreeS Family Funding News · Vol 8
Walk alongside more outstanding founders.
September, When Hope Will Break Through Like the Sun | 5Y News Monthly
The big news from last month.
Source Code Capital portfolio company Galixir announced the completion of a new funding round, with existing shareholder Source Code Capital continuing to increase its stake.
Continuously exploring the application of AI technology to empower innovative drug R&D
5Y News | Galixir Completes New Strategic Funding Round, Continues Advancing Drug R&D Pipeline
5Y Capital continues to watch for opportunities where information technology can be applied in healthcare and medicine.
5Y News｜Deepexi Completes $40 Million Series A4 Round
Deepexi raised $40 million in its Series A4 round. We talked about why organizational building matters.
